Acquisition Announced
Eli Lilly and Company acquisition of CrossBridge Bio
US$300m consideration
Announced 14 Apr 2026
Advisers
CrossBridge Bio
Target
- Legal adviser
Eli Lilly and Company
Acquirer
Not disclosed
- Target
- CrossBridge Bio
- Acquirer
- Eli Lilly and Company
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
Sources
- 14 Apr 2026 CrossBridge Bio Acquired by Eli Lilly and Co. for up to $300 Million cooley.com